# Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT03600155** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03600155
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2024-12-02
- **Final completion:** 2024-12-02
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600155, "Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03600155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*